Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
190 studies found for:    "Duchenne muscular dystrophy"
Show Display Options
Rank Status Study
1 Not yet recruiting An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Intervention: Biological: PF-06252616
2 Recruiting A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Interventions: Biological: PF-06252616;   Drug: Placebo
3 Completed High-dose Prednisone in Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Intervention: Drug: Prednisone
4 Withdrawn Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.GALGT2
Condition: Duchenne Muscular Dystrophy
Interventions: Biological: rAAVrh74.MCK.GALGT2;   Other: PLACEBO (Saline)
5 Unknown  Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Intervention: Biological: human umbilical cord mesenchymal stem cells
6 Recruiting An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Condition: Duchenne Muscular Dystrophy
Interventions: Drug: Vamorolone 0.25 mg/day/day;   Drug: Vamorolone 0.75 mg/day/day;   Drug: Vamorolone 2.0 mg/day/day;   Drug: Vamorolone 6.0 mg/day/day
7 Recruiting A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Condition: Duchenne Muscular Dystrophy
Interventions: Drug: Vamorolone 0.25 mg/kg/day;   Drug: Vamorolone 0.75 mg/kg/day;   Drug: Vamorolone 2.0 mg/kg/day;   Drug: Vamorolone 6.0 mg/kg/day
8 Completed Stem Cell Therapy in Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Intervention: Biological: Stem Cell
9 Active, not recruiting Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients
Condition: Duchenne Muscular Dystrophy
Interventions: Drug: SRP-4045;   Drug: Placebo
10 Completed Safety Study of Flavocoxid in Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Intervention: Drug: Flavocoxid
11 Active, not recruiting Sunphenon Epigallocatechin-Gallate (EGCg) in Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Interventions: Drug: Epigallocatechin-Gallate;   Drug: Placebo
12 Recruiting Study of DS-5141b in Patients With Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Intervention: Drug: DS-5141b
13 Completed Safety and Efficacy Study of PTC124 in Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Intervention: Drug: PTC124
14 Not yet recruiting Analysis of a Virtual Reality Task in Patients With Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Interventions: Device: Acquisition on TouchScreen;   Device: Acquisition on Kinect;   Device: Acquisition on LeapMotion
15 Recruiting Observational Study of Patients With Duchenne Muscular Dystrophy Theoretically Treatable With Exon 53 Skipping
Condition: Duchenne Muscular Dystrophy
Intervention:
16 Unknown  Safety and Efficacy Study of IGF-1 in Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Interventions: Drug: IGF-1;   Other: Standard steroid treatment
17 Recruiting Plus Epicatechin Duchenne Muscular Dystrophy in Non-ambulatory Adolescents
Condition: Duchenne Muscular Dystrophy
Intervention: Drug: (+)- Epicatechin
18 Terminated Open Label, Extension Study of PRO044 in Duchenne Muscular Dystrophy (DMD)
Condition: Duchenne Muscular Dystrophy
Interventions: Drug: PRO044 SC 6 mg/kg;   Drug: PRO044 IV 6 mg/kg;   Drug: PRO044 IV 9 mg/kg
19 Completed Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Intervention: Drug: AVI-4658 (PMO)
20 Terminated Phase IIb Study of PRO045 in Subjects With Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Interventions: Drug: PRO045, 0.15 mg/kg/week;   Drug: PRO045, 1.0 mg/kg/week;   Drug: PRO045, 3.0 mg/kg/week;   Drug: PRO045, 6.0 mg/kg/week;   Drug: PRO045, 9.0 mg/kg/week;   Drug: PRO045, selected dose

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.